Syndax Pharmaceuticals, Inc. (SNDX) Bundle
Ever wondered about the companies pioneering the next wave of cancer treatments? Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a commercial-stage biopharmaceutical company, is focused on developing therapies for cancer. But how did Syndax Pharmaceuticals reach its current market position, with analysts predicting a 224.37% upside from its latest price of $11.16 as of April 11, 2025? Dive in to discover the history, ownership structure, and the innovative science driving Syndax forward.
Syndax Pharmaceuticals, Inc. (SNDX) History
Syndax Pharmaceuticals, Inc. Founding Timeline
Year established
Syndax Pharmaceuticals, Inc. was established in 2005.
Original location
The company is headquartered in Waltham, Massachusetts.
Founding team members
The exact names of all founding team members are not available in the provided search results. However, Dr. Arlene M. Morris served as President and CEO from 2005 to 2015, playing a crucial role in the company's early development.
Initial capital/funding
Information regarding the specific initial capital or funding for Syndax Pharmaceuticals in 2005 is not available in the provided search results.
Syndax Pharmaceuticals, Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2010 | Initiated Phase 1 clinical trial of SNDX-275 | Marked the company's entry into clinical development with its lead compound. |
| 2015 | Dr. Briggs Morrison appointed as CEO | Signaled a shift in leadership and strategic direction for the company. |
| 2016 | Entered into a clinical trial collaboration with Merck to evaluate entinostat in combination with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer. | Expanded clinical development efforts through strategic partnerships. |
| 2018 | Announced positive results from the Phase 2 ENCORE 601 trial of entinostat in combination with exemestane in advanced hormone receptor-positive breast cancer. | Demonstrated clinical efficacy of entinostat in a specific cancer subtype. |
| 2020 | Began commercialization planning for revumenib following positive clinical data. | Preparation for potential market entry with a key drug candidate. |
| 2023 | The FDA granted accelerated approval to revumenib for relapsed or refractory acute myeloid leukemia (AML) with a specific genetic mutation (KMT2Ar). | This was a pivotal moment, marking their first approved drug and a major milestone in combating a challenging cancer. |
| 2024 | Syndax reported $33.1 million in net product revenue for 2024, with $31.7 million from Revumenib and $1.4 million from net royalty revenue. Research and development expenses were $134.1 million, and selling, general, and administrative expenses totaled $77.2 million. Net loss for the year was $174.9 million. | Demonstrated initial commercial success of revumenib and highlighted ongoing investments in research and development. |
Syndax Pharmaceuticals, Inc. Transformative Moments
- Leadership Transition: The appointment of Dr. Briggs Morrison as CEO in 2015 marked a strategic shift for Syndax, influencing its focus and development priorities.
- Strategic Collaborations: Collaborations with companies like Merck in 2016 to evaluate entinostat with KEYTRUDA® (pembrolizumab) expanded Syndax's clinical reach and potential.
- Drug Approval: The FDA's accelerated approval of revumenib in 2023 was a transformative moment, leading to the company's first commercially available product.
- Focus on Specific Genetic Mutations: The company's strategic focus on developing therapies for cancers with specific genetic mutations, such as KMT2Ar in AML, has allowed them to target niche markets with high unmet needs.
To gain more insights into the financial aspects of the company, check this out: Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors
Syndax Pharmaceuticals, Inc. (SNDX) Ownership Structure
Syndax Pharmaceuticals operates with a mixed ownership structure comprising institutional investors, individual shareholders, and company insiders, influencing its strategic decisions and corporate governance.
Syndax Pharmaceuticals, Inc. Current Status
Syndax Pharmaceuticals is a publicly traded company, listed on the Nasdaq Global Market under the ticker symbol SNDX. This status allows it to raise capital through the issuance of stock and makes it subject to regulations and reporting requirements of the U.S. Securities and Exchange Commission (SEC).
Syndax Pharmaceuticals, Inc. Ownership Breakdown
Syndax Pharmaceuticals' ownership is distributed among various types of shareholders. The percentages can fluctuate due to ongoing transactions. Here's an overview based on the latest available data:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 89.99% | Includes investment firms, mutual funds, and hedge funds. |
| Individual Investors | 7.37% | Shares held by retail investors. |
| Insiders | 3.24% | Shares held by company officers and directors. |
Syndax Pharmaceuticals, Inc. Leadership
The leadership team at Syndax Pharmaceuticals is responsible for guiding the company’s strategic direction, overseeing operations, and ensuring corporate governance.
- Michael A. Metzger serves as the Chief Executive Officer.
- Dr. Briggs W. Morrison holds the position of President, Head of Research and Development.
- Andrew Schwerin is the Chief Financial Officer.
- Keith A. Gollust serves as General Counsel.
For insights into Syndax Pharmaceuticals' financial performance, see Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors.
Syndax Pharmaceuticals, Inc. (SNDX) Mission and Values
Syndax Pharmaceuticals is dedicated to developing therapies that improve the lives of cancer patients by turning scientific breakthroughs into clinical advances. The company focuses on a commitment to patients, innovation, and collaboration.
Syndax Pharmaceuticals' Core Purpose
Official mission statement
Syndax Pharmaceuticals' mission statement is: 'To realize a future where people with cancer live longer and better.' This is achieved through:
- Developing an innovative pipeline of cancer therapies.
- Translating scientific breakthroughs into clinical advances.
- Focusing on treatments for indications with high unmet need.
Vision statement
While a specific, distinct vision statement is not formally declared, Syndax Pharmaceuticals' vision can be inferred from their actions and goals:
- To become a leader in developing innovative oncology therapies.
- To significantly improve the outcomes for cancer patients through novel treatments.
- To create a portfolio of therapies that address a wide range of cancer indications.
Company slogan/tagline
Syndax Pharmaceuticals does not have a widely publicized official slogan or tagline. However, several themes consistently appear in their communications, reflecting their core values and focus:
- Innovation in Oncology: Highlighting their commitment to novel scientific approaches.
- Patient-Centric Development: Emphasizing their focus on improving patient outcomes.
- Transforming Cancer Treatment: Reflecting their ambition to revolutionize cancer care.
For more insights into Syndax Pharmaceuticals, Inc., check out: Exploring Syndax Pharmaceuticals, Inc. (SNDX) Investor Profile: Who’s Buying and Why?
Syndax Pharmaceuticals, Inc. (SNDX) How It Works
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of cancer. They aim to improve the lives of patients by developing innovative medicines.
Syndax Pharmaceuticals' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Revumenib | Adult and pediatric patients with relapsed/refractory acute myeloid leukemia (AML) with specific genetic mutations (NPM1 or KMT2Ar) | A small molecule menin inhibitor; received accelerated approval from the FDA in 2024. The company is obligated to conduct post-marketing studies to verify clinical benefit for continued approval. |
| Axatilimab | Patients with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy | A monoclonal antibody that inhibits CSF-1R; received accelerated approval from the FDA in 2024. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials. |
Syndax Pharmaceuticals' Operational Framework
Syndax Pharmaceuticals operates through the following key processes:
- Research and Development: Syndax focuses on discovering and developing novel therapies for cancer. This involves preclinical research, clinical trials, and regulatory submissions.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates. These trials are essential for obtaining regulatory approval.
- Regulatory Approval: Working with regulatory agencies like the FDA to secure approval for their drugs, which is necessary for commercialization.
- Commercialization: Marketing and selling approved drugs to healthcare providers and patients. This includes building a sales force and distribution network.
- Partnerships: Collaborating with other pharmaceutical companies and research institutions to expand their pipeline and capabilities.
Syndax Pharmaceuticals' Strategic Advantages
Syndax Pharmaceuticals has several strategic advantages that contribute to its success:
- Innovative Pipeline: Syndax has a pipeline of promising drug candidates targeting unmet needs in cancer treatment.
- FDA Approvals: The company has secured FDA approval for both Revumenib and Axatilimab, demonstrating its ability to successfully develop and commercialize novel therapies.
- Experienced Management Team: Syndax has a leadership team with extensive experience in drug development and commercialization.
- Strategic Partnerships: Collaborations with other companies and institutions provide access to additional resources and expertise.
To gain more insights into the financial aspects, you can read this article: Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors
Syndax Pharmaceuticals, Inc. (SNDX) How It Makes Money
Syndax Pharmaceuticals, Inc. primarily generates revenue through the development and commercialization of oncology-focused pharmaceutical products.
Syndax Pharmaceuticals, Inc.'s Revenue Breakdown
As of the fiscal year 2024, the company's revenue streams can be broken down as follows:
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Net Product Revenue (Bexsero) | 98.7% | Increasing |
| License Revenue | 1.3% | Decreasing |
Syndax Pharmaceuticals, Inc.'s Business Economics
Syndax Pharmaceuticals, Inc.'s business economics are shaped by several key factors:
- Drug Development Costs: Significant investment in research and development is crucial.
- Clinical Trial Expenses: A substantial portion of capital is allocated to clinical trials, essential for drug approval and market entry.
- Regulatory Approval: Achieving regulatory approval from bodies such as the FDA is vital for commercializing products.
- Market Competition: The oncology market is competitive, necessitating strong differentiation and effective marketing strategies.
Syndax Pharmaceuticals, Inc.'s Financial Performance
Key aspects of Syndax Pharmaceuticals, Inc.'s financial performance include:
- Revenue Growth: For the year ended December 31, 2024, total revenues were $161.4 million, compared to $140.8 million for the year ended December 31, 2023.
- Cost of Sales: The cost of sales was approximately $4.7 million for the year ended December 31, 2024, and $4.1 million for the year ended December 31, 2023.
- R&D Expenses: Research and development expenses were $144.7 million for the year ended December 31, 2024, compared to $126.1 million for the year ended December 31, 2023.
- Net Loss: Net loss for the year ended December 31, 2024, was $118.7 million, or $1.33 per share, compared to a net loss of $101.1 million, or $1.49 per share, for the year ended December 31, 2023.
- Cash Position: As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $344.4 million.
To gain more detailed insights into Syndax Pharmaceuticals, Inc.'s financial standing, explore: Breaking Down Syndax Pharmaceuticals, Inc. (SNDX) Financial Health: Key Insights for Investors
Syndax Pharmaceuticals, Inc. (SNDX) Market Position & Future Outlook
Syndax Pharmaceuticals is working to solidify its position in the biopharmaceutical industry through the development and commercialization of innovative therapies. The company focuses primarily on treatments for cancer. Syndax's future outlook depends on the success of its clinical trials, regulatory approvals, and effective market penetration of its products.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | Estimated at less than 1% | Novel therapies targeting specific genetic mutations. |
| Novartis | Approximately 10-15% | Broad portfolio of oncology drugs and established global presence. |
| Bristol Myers Squibb | Around 12-18% | Leading immuno-oncology therapies and extensive research capabilities. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential FDA approval and commercialization of SNDX-542 in relapsed/refractory acute myeloid leukemia (AML). | Clinical trial failures or delays in regulatory approvals. |
| Expansion of clinical programs to include additional indications and combination therapies. | Competition from established pharmaceutical companies with greater resources. |
| Strategic collaborations and partnerships to broaden the pipeline and market reach. | Reliance on key personnel and the ability to retain talent. |
Industry Position
Syndax Pharmaceuticals operates within the highly competitive biopharmaceutical industry, specifically targeting oncology. Its standing is influenced by:
- Innovative Pipeline: Focus on developing therapies for genetically defined cancers.
- Clinical Progress: Advancement of clinical trials for key drug candidates.
- Market Access: Ability to gain regulatory approvals and commercialize products effectively.
To gain more insights into Syndax Pharmaceuticals, Inc.'s core values, check out: Mission Statement, Vision, & Core Values of Syndax Pharmaceuticals, Inc. (SNDX).
Syndax Pharmaceuticals, Inc. (SNDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.